Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Apr 14;18(4):837.
doi: 10.3390/ijms18040837.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Antonio M Almeida  1 , Thomas Prebet  2 , Raphael Itzykson  3 , Fernando Ramos  4 , Haifa Al-Ali  5 , Jamile Shammo  6 , Ricardo Pinto  7 , Luca Maurillo  8 , Jaime Wetzel  9 , Pellegrino Musto  10 , Arjan A Van De Loosdrecht  11 , Maria Joao Costa  12 , Susana Esteves  13 , Sonja Burgstaller  14 , Reinhard Stauder  15 , Eva M Autzinger  16 , Alois Lang  17 , Peter Krippl  18 , Dietmar Geissler  19 , Jose Francisco Falantes  20 , Carmen Pedro  21 , Joan Bargay  22 , Guillermo Deben  23 , Ana Garrido  24 , Santiago Bonanad  25 , Maria Diez-Campelo  26 , Sylvain Thepot  27 , Lionel Ades  28 , Wolfgang R Sperr  29 , Peter Valent  30 , Pierre Fenaux  31 , Mikkael A Sekeres  32 , Richard Greil  33   34   35   36 , Lisa Pleyer  37   38   39   40
Affiliations
Multicenter Study

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Antonio M Almeida et al. Int J Mol Sci. .

Abstract

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

Keywords: acute erythroleukemia; azacitidine; decitabine.

PubMed Disclaimer

Conflict of interest statement

Antonio M. Almeida: speaker and advisory board for Celgene; Arjan A. Van De Loosdrecht: speaker and advisory board Celgene, advisory board Novartis; Jamile Shammo: Received research funding and honoraria for speaking engagements and consultancy from Celgene; Peter Valent received a research grant and speaker´s honoraria from Celgene and served as an advisory board member for Celgene. Fernando Ramos: Honoraria/Consultation fees for Celgene, Janssen, Amgen, Novatis, Pfizer, Glaxo-Smith-Kline, Merck-Sharp & Dohme. Maria Diez Campelo: speaker, research founding and advisory boards for Celgene.

Figures

Figure 1
Figure 1
(A) Overall survival of HMA-treated patients stratified by cytogenetic risk group (total HMA cohort): the median OS for patients treated with HMA was superior for patients with intermediate-compared to high-risk cytogenetics (13.5 months vs. 12.3 months; p = 0.0376); and (B) the overall survival by response to HMA: the median survival in patients with CR was 18.2 months, 12.7 months in patients with PR or HI, and 4.5 months in patients with no response (SD or primary PD; p < 0.001).
Figure 1
Figure 1
(A) Overall survival of HMA-treated patients stratified by cytogenetic risk group (total HMA cohort): the median OS for patients treated with HMA was superior for patients with intermediate-compared to high-risk cytogenetics (13.5 months vs. 12.3 months; p = 0.0376); and (B) the overall survival by response to HMA: the median survival in patients with CR was 18.2 months, 12.7 months in patients with PR or HI, and 4.5 months in patients with no response (SD or primary PD; p < 0.001).
Figure 2
Figure 2
Overall survival of AEL patients stratified by type of first line treatment. (A) Total cohorts: median OS for patients treated with first-line HMA was similar to that of those treated with first-line ICT (13.7 months vs. 10.5 months; p = 0.564); (B) stratified by MRC intermediate cytogenetic risk: AEL-patients with intermediate-risk cytogenetics treated with first-line HMA did not have a significantly different median survival as compared to AEL-patients treated with first-line ICT (16.9 months vs. 29.3 months; p = 0.277); and (C) stratified by MRC high cytogenetic risk: AEL-patients with high-risk cytogenetics treated with first-line HMA had a significantly longer median survival as compared to AEL-patients treated with first-line ICT (13.3 months vs. 7.5 months; p = 0.0391).
Figure 2
Figure 2
Overall survival of AEL patients stratified by type of first line treatment. (A) Total cohorts: median OS for patients treated with first-line HMA was similar to that of those treated with first-line ICT (13.7 months vs. 10.5 months; p = 0.564); (B) stratified by MRC intermediate cytogenetic risk: AEL-patients with intermediate-risk cytogenetics treated with first-line HMA did not have a significantly different median survival as compared to AEL-patients treated with first-line ICT (16.9 months vs. 29.3 months; p = 0.277); and (C) stratified by MRC high cytogenetic risk: AEL-patients with high-risk cytogenetics treated with first-line HMA had a significantly longer median survival as compared to AEL-patients treated with first-line ICT (13.3 months vs. 7.5 months; p = 0.0391).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Santos F.P., Bueso-Ramos C.E., Ravandi F. Acute erythroleukemia: Diagnosis and management. Expert Rev. Hematol. 2010;3:705–718. doi: 10.1586/ehm.10.62. - DOI - PubMed
    1. Liu W., Hasserjian R.P., Hu Y., Zhang L., Miranda R.N., Medeiros L.J., Wang S.A. Pure erythroid leukemia: A reassessment of the entity using the 2008 World Health Organization classification. Mod. Pathol. 2011;24:375–383. doi: 10.1038/modpathol.2010.194. - DOI - PubMed
    1. Zuo Z., Polski J.M., Kasyan A., Medeiros L.J. Acute erythroid leukemia. Arch. Pathol. Lab. Med. 2010;134:1261–1270. - PubMed
    1. Kasyan A., Medeiros L.J., Zuo Z., Santos F.P., Ravandi-Kashani F., Miranda R., Vadhan-Raj S., Koeppen H., Bueso-Ramos C.E. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod. Pathol. 2010;23:1113–1126. doi: 10.1038/modpathol.2010.96. - DOI - PMC - PubMed
    1. Selby D.M., Valdez R., Schnitzer B., Ross C.W., Finn W.G. Diagnostic criteria for acute erythroleukemia. Blood. 2003;101:2895–2896. doi: 10.1182/blood-2002-11-3459. - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts